Company Description
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases.
The company’s lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells.
It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency.
Jasper Therapeutics, Inc. was founded in 2018 and is based in Redwood City, California.
| Country | United States |
| Founded | 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 27 |
| CEO | Jeetinder Mahal |
Contact Details
Address: 2200 Bridge Pkwy, Suite 102 Redwood City, California 94065 United States | |
| Phone | 650 549 1400 |
| Website | jaspertx.com |
Stock Details
| Ticker Symbol | JSPR |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1788028 |
| CUSIP Number | 471871103 |
| ISIN Number | US4718712023 |
| Employer ID | 84-2984849 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Jeetinder Singh Mahal M.B.A. | President, Chief Operating Officer, Chief Executive Officer and Director |
| Thomas G. Wiggans | Executive Chairman |
| Dr. Judith Anne Shizuru M.D., Ph.D. | Co-Founder, Member of Scientific Advisory Board and Director |
| Herbert C. Cross CPA | Chief Financial Officer and Corporate Secretary |
| Alex Gray | Head of Investor Relations |
| Matthew Ford | Senior Vice President of Human Resources |
| Dr. Daniel C. Adelman M.D. | Acting Chief Medical Officer, Member of Scientific Advisory Board and Senior Clinical Advisor |
| Dr. Luca Di Noto Ph.D. | Senior Vice President of Technical Operations |
| Patricia Carlos | Senior Vice President of Regulatory Affairs and Quality |
| Kimberly Baxter | Vice President and Head of Quality |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 25, 2026 | SCHEDULE 13G | Filing |
| Feb 18, 2026 | SCHEDULE 13D/A | Filing |
| Feb 12, 2026 | SCHEDULE 13G | Filing |
| Feb 11, 2026 | SCHEDULE 13G | Filing |
| Jan 26, 2026 | SCHEDULE 13G/A | Filing |
| Jan 8, 2026 | 8-K | Current Report |
| Jan 7, 2026 | 8-K | Current Report |
| Dec 2, 2025 | SCHEDULE 13G | Filing |
| Dec 2, 2025 | 8-K | Current Report |
| Nov 14, 2025 | SCHEDULE 13G/A | Filing |